This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Prescribing information for Fragmin® (dalteparin sodium) can be found here. Adverse event reporting can be found at the bottom of the page.
Anticoagulation could be vital in managing VTE risk in your cancer patients. But cancer patients are also at risk of bleeding. So, for clinicians, balancing thrombosis and bleeding risk can be notoriously difficult.
What else might increase VTE or bleeding in your patients? How can you assess your patient and balance these throughout cancer treatment? To find out more about epidemiology and risk factors visit Cancer associated thrombosis patient risk
There is a controlled balance among natural anticoagulants, fibrin formation, fibrinolysis and platelet function to maintain haemostasis.1
Paradoxically, cancer can be associated with both excessive bleeding and thrombosis.1
Tumour cells can induce clot-promoting properties of other cells, stimulating direct cell-to-cell interactions with the endothelium, platelets, or reticuloendothelial cells leading to thrombus formation.2
On the other end of the spectrum, bleeding is observed in about 10% of patients with solid tumours and in a higher proportion in patients with hematologic malignancies.2
Potential causes of bleeding include thrombocytopenia, decreased synthesis of coagulation factors due to liver dysfunction, vitamin K deficiency, or pre-existing genetic disorders.2
You will need to consider these factors, in the context of each individual patient, to ensure tailored treatment for VTE.2
Cancer patients have an increased risk of bleeding. Therefore, caution must be exercised when using anticoagulant therapy to reduce risk of VTE.3
Treatment or prophylaxis of VTE for patients with cancer must always balance the risk of recurrent VTE events with the increased risk of anticoagulant-related bleeding and take into consideration the consequences of these outcomes (including mortality, financial cost, quality of life), as well as patient values and preferences.4
Managing VTE in cancer is not a one-size-fits all approach and must be evaluated on an individual basis.5
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024